Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

QUEBEC CITY, Canada, June 11, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech” or the “Company”) (Nasdaq: LDTC), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), today announces that, as a result of the cessation of the Company’s discussions with a significant potential commercial counterpart and in light of the Company’s current financial position, the Company has laid off most of its employees and will no ...

Core Insights - Ocugen, Inc. is set to present at the 2025 BIO International Convention, showcasing its innovative gene therapies for blindness diseases [1][2] - The company has recently executed a binding term sheet for exclusive rights to OCU400 in Korea, indicating a strategic partnership aimed at enhancing its market presence [3] - Ocugen's modifier gene therapy platform has achieved significant milestones, including FDA alignment for a pivotal trial and nearing completion of enrollment for the OCU400 Phase 3 clinical trial, with plans to file a Biologics License Application by mid-2026 [3] Company Overview - Ocugen, Inc. specializes in gene therapies for blindness diseases, focusing on inherited retinal diseases and conditions affecting millions globally, such as retinitis pigmentosa and Stargardt disease [6] - The company's modifier gene therapy platform is designed to address complex diseases caused by imbalances in multiple gene networks, distinguishing it from traditional gene therapies [6] Conference Details - Dr. Shankar Musunuri, Chairman and CEO, will present on June 16, 2025, and participate in panel discussions on optimizing clinical outcomes and navigating the regulatory landscape during the convention [4][5]

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . Analyst's Disclosure:I/we have a beneficial long position in the shares of TPL, LB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha ...

Core Viewpoint - Matador Technologies Inc. has acquired an additional 5.38 bitcoin for CAD$798,000 (USD$581,198), bringing its total Bitcoin holdings to approximately 69 bitcoin, reinforcing its long-term capital preservation strategy [1][2]. Financial Position - The company operates debt-free, with all Bitcoin holdings free and clear, and maintains cash reserves of approximately CAD$6.5 million and physical gold holdings of 2 kilograms (approximately CAD$319,000) [2][3]. - The recent acquisition of Bitcoin was made at an average price of USD$107,217 per bitcoin, inclusive of fees and expenses [1]. Strategic Investments - Matador has committed to invest in HODL Systems, a publicly traded Indian technology company, which would provide up to 24.95% ownership, enhancing its exposure to the global digital asset ecosystem [3][6]. - This investment aligns with the company's goal of deepening its commitment to Bitcoin as a reserve asset and expanding its treasury holdings [6]. Long-term Strategy - The company integrates Bitcoin into its long-term strategy as a core treasury asset and aims to leverage blockchain technology to deliver long-term value for stakeholders [4][5]. - Matador's strategy includes strategic Bitcoin accumulation, product development, and participation in digital asset infrastructure, driving long-term shareholder value without dilution [5].

Myriad Uranium Reports Final Chemical Assays from Copper Mountain. Grades Up to 60% Higher Than Probe Equivalents, with Positive Implications for Scale and Scope of the Project. Plan of Operations Application Submitted to Drill High Priority Prospects June 11, 2025 7:30 AM EDT | Source: Myriad Uranium Corp. Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Myriad Uranium Corp. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) is pleased to report chemical assay results from the final six boreholes drilled in ...

Core Insights - Snap is set to release augmented reality (AR) glasses in 2026, following a significant investment of over $3 billion and 11 years of development [2][5][10] - The new AR glasses, known as Specs, will be lighter and more advanced than previous versions, which were only available to developers [2][5] - Snap's CEO, Evan Spiegel, emphasizes the need to integrate AI into the real world through AR technology [4] Company Developments - Snap's revenue increased by 14% from $1.19 billion in 2024 to $1.36 billion in the first quarter of this year, while net losses decreased by 54% to $140 million [11] - The company has over 900 million monthly active users and 460 million daily active users, indicating a strong user base for potential AR product adoption [11] - Snap's stock has faced challenges, dropping more than 24% this year, partly due to economic uncertainties affecting advertising spending [10] Industry Context - The AR glasses market is competitive, with major tech companies like Meta, Google, and Apple also developing similar products [5][8] - Previous attempts at smart glasses, such as Google Glass and Snap's earlier Spectacles, struggled to gain consumer traction, but advancements in technology may improve future adoption [6][8] - The ongoing development of AR glasses is seen as a potential new revenue stream for Snap beyond digital advertising [10]

Jiayin Group (NASDAQ: JFIN ), a fintech company operating primarily in China, released its Q1 FY2025 report on June 4, which included, among other things, a whopping EPS increase of almost 100% QoQ. The outstanding results got a strong response from theWelcome to my author's site. As an avid follower of SeekingAlpha, I take great interest in articles posted as the subject matter is often something that appeals to me. However, I will sometimes encounter an article that I might not agree with. My purpose is t ...

Adjustment of expectations RIAS A/S Attachment 2025 06 Justering RIAS AS_UK vers. ...

D-Wave Quantum TodayQBTSD-Wave Quantum$16.96 -0.99 (-5.49%) 52-Week Range$0.75▼$19.77Price Target$10.17Add to WatchlistShares of D-Wave Quantum NYSE: QBTS experienced an epic journey in the first five months of 2025 amid both good news and outspoken bearish critique. As of mid-June, though, the bulls seem to be winning: shares of QBTS are up nearly 87% year-to-date (YTD) and an astonishing 1,400% in the past 12 months. Although all six analysts who have recently reviewed D-Wave rate it as a Buy, suggesting ...